Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma

<div>Levels of IDH1 expression in PRAD. Relative expression of IDH1in PRAD cells and tissues based on multiple databases. (a) Distribution of IDH1 CERES scores (<i>y</i>-axis) in prostate cancer cell lines. Six of 8 cell lines screened in CRISPR cell lines have a greater than 75% probability of being dependent on IDH1. (b) The mRNA detects the expression level of different prostate cancer cells. (c) Comparison of immunohistochemical images of IDH1 in PRAD tissues of six different patients based on human protein atlas.</div>

Journal of Oncology

fig3

Figure 3

Figure 3: Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma 

Figure 3 | Integrative Multiomics Evaluation of IIDH1 Metabolic Enzyme as a Candidate Oncogene That is Correlated with Poor Prognosis and Immune Infiltration in Prostate Adenocarcinoma 